Cite
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
MLA
Geoffrey L. Uy, et al. “A Phase 2 Study Incorporating Sorafenib into the Chemotherapy for Older Adults with FLT3-Mutated Acute Myeloid Leukemia: CALGB 11001.” Blood Advances, vol. 1, no. 5, Jan. 2017, pp. 331–40. EBSCOhost, https://doi.org/10.1182/bloodadvances.2016003053.
APA
Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, & Richard A. Larson. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331–340. https://doi.org/10.1182/bloodadvances.2016003053
Chicago
Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, et al. 2017. “A Phase 2 Study Incorporating Sorafenib into the Chemotherapy for Older Adults with FLT3-Mutated Acute Myeloid Leukemia: CALGB 11001.” Blood Advances 1 (5): 331–40. doi:10.1182/bloodadvances.2016003053.